Prognostic value of renal and cardiac biomarkers is ascertained in recognizing high risk patients with acute heart disorders. Thoughtful use of cardiorenal biomarkers allows not only diagnostic assessment of acute cardiac patients with potential worsening of renal function but also monitoring of renal disease progression in this patient population. As these patients with acute heart disorders may need more strategic and tailored treatment in order to prevent future risk of an adverse event, novel cardiac and renal biomarkers can be helpful on this matter.
Introduction
Acute heart failure (AHF) and acute coronary syndrome (ACS), especially myocardial infarction are serious lifethreating cardiovascular diseases. Renal impairment is common in these patients since the kidney represents an important part of fluid and sodium transfer system in the human body (1, 2) . Chronic kidney disease (CKD) and the lethal outcome is more likely to be found in patients with heart failure (HF) in comparison with individuals without HF (3) . Worsening of renal function is associated with an increased risk of in-hospital death, HF and cardiogenic shock in patients with ACS (4) . According to a recent metaanalysis, acute kidney injury (AKI) occurred in 35 .3% of AHF patients, 22 .1% of cardiac surgery patients and 12.7% of ACS patients (5) . New onset AKI in acute cardiac patients was linked with 5-times increased mortality risk. Furthermore, if acute cardiac patients diagnosed with AKI underwent renal replacement therapy (RRT), the risk of mortality was doubling (5) .
Assessment of renal and cardiac biomarkers offers prognostic information in different fields of medicine such as cardiac surgery, intensive coronary units (ICUs), and transplantation (6-8). Nevertheless, prediction of adverse future events in patients with acute heart disorders remains challenging. Several candidates among biologic markers with promising prognostic potential in acute cardiac events have emerged in recent years (9) . However, to our best knowledge, there is only one investigation that assessed the ability of biomarkers to predict overall and renal survival in patients admitted to ICU for the reason of acute cardiac events. However, postdischarge need for dialysis was not observed in this study (10) .
Objectives
This investigation aimed to examine the role of renal injury biomarkers (serum cystatin C, serum and urine interleukin-18, IL-18) and HF biomarkers (plasma B-type natriuretic peptide, BNP) in the prediction of the postdischarge requirement of RRT and/or 6-month mortality in patients with acute heart disorders admitted to ICUs.
Patients and methods

Design and population of the study
The study was designed as a prospective and observational study. It was performed at the ICUs of the Heart Disease Clinic and Nephrology Clinic of the Clinical Center University of Sarajevo (CCUS). All consecutive patients admitted to ICUs with the diagnosis of AHF and/ or ACS during the 7-months period were eligible for enrollment. The inclusion criteria were patients older than 18 years diagnosed with AHF and/or ACS with the length of hospital stay longer than 48 hours. The exclusion criteria were end-stage kidney disease, renal transplant, preexisting dialysis before ICUs admission, or missing admission data. All subjects signed informed consent.
Laboratory and Biomarker Measurements
Measurements of serum creatinine were obtained at admission, 48 hours and 7 days after admission, as well as at discharge. The leukocytes, hemoglobin, sodium, blood urea nitrogen (BUN), albumin, C-reactive protein (CRP), uric acid, troponin I were measured at admission. 24hour urine output was measured during hospitalization. Proteinuria, albuminuria, and biomarker measurements were obtained in the first 24-hours of hospital stay. Measurements of cystatin C in serum, as well as IL-18 in serum and urine, were performed by ELISA (R&D Systems). Plasma BNP level was measured by microparticle immunoassay method (Abbott Laboratories).
Definitions
AHF was defined using the European Society of Cardiology Criteria (11) . The diagnosis of ACS encompassed unstable angina, non-ST-segment-elevation myocardial infarction, and ST-segment-elevation myocardial infarction. The acute myocardial infarction was defined using the consensus of the recommendations of international experts in the field of cardiology (12) .
The Chronic Kidney Disease Epidemiology Collaboration equation was used to calculate estimated glomerular filtration rate (eGFR) (13) . CKD was recorded in individuals with documented eGFR <60 mL/min and a history of CKD that lasted at least three months. Antecedents of hypertension, diabetes mellitus, and anemia were recorded for all patients. Anemia was defined as a plasma hemoglobin concentration <135 g/L in men (<132 g/L in men over the age of 70) or <120 g/L in women. Charlson comorbidity index (CCI) score was used to assess the presence of comorbid conditions (14) . The Acute Physiology and Chronic Health Evaluation (APACHE) II score was used to assess the severity of illness (15) . Transthoracic echocardiographic measurements were performed according to the available published guidelines. Internal dimensions were obtained with two-dimensional echocardiography guided M-mode approach (16) . Left ventricular systolic function was assessed by calculating ejection fraction (EF). EF of <50% was suggestive of abnormal left ventricular systolic function, and EF <35% was considered as severe systolic dysfunction. Using the transmitral flow signal, peak early diastolic velocity (E), peak late diastolic velocity (A), and the E/A ratio were measured. An E/A ratio <1 was suggestive of abnormal left ventricular diastolic function. Further categorization of abnormal left ventricular diastolic function encompassed abnormal relaxation, pseudo-normalization and restrictive filling (17) .
Outcome definitions
Because the majority of patients in ICUs received diuretics, AKI was defined according to Acute Kidney Injury Network (AKIN) criteria based on serum creatinine values. AKI was diagnosed within the first 48 hours of hospitalization in patients with a detected increase in serum creatinine of 0.3 mg/dL (≥26.4 μmol/L) or more, or in patients with the percentage increase in serum creatinine of 50% (1.5-fold from baseline) or more (18) .
In-hospital mortality was recorded. Patients treated with acute RRT during hospital stay were recorded. Hospital survivors were followed up six months after discharge. The composite outcome was the post-discharge need for RRT and/or 6-month mortality. According to the composite outcome, we created two groups of patients: renal and/or overall nonsurvivors and renal and/or overall survivors. Patients who continued RRT and/or died at any point during 6-month follow up were considered to be renal and/or overall nonsurvivors, while patients who were not treated with RRT and/or survived during 6-month follow up were considered to be renal and/or overall survivors.
Ethical issues
The research was conducted according to the criteria set by the Declaration of Helsinki. It was approved by the Medical Ethics Committee of the Clinical Center University of Sarajevo (0207-27144).
Statistical analysis
Statistical analysis were performed with SPSS software version 17.0 (SPSS, Inc., Chicago, Illinois). Continuous variables with normal distribution were expressed as mean ± standard deviation, and continuous variables whose distribution was not normal were expressed as median (interquartile range). Categorical variables were expressed as a number (percentage). To compare continuous variables with normal distribution, a twosample t test was used, and for continuous variables whose distribution was not normal, a Mann-Whitney U test was used. To compare categorical variables, the chi-square or Fisher's exact test was used. The independent prognostic values of renal and cardiac biomarkers, echocardiographic parameters as well as illness severity and comorbidity scores were assessed by univariate Cox proportional hazards regression analysis, followed by multivariate Cox proportional hazards regression analysis which included variables that were associated with outcomes in univariate analysis. Kaplan-Meier analysis was performed when patients were stratified based on quartiles of urine IL-18 levels and based on median plasma BNP; the differences between survival and event-free rate curves were analyzed by log-rank test. The sensitivity and specificity of urine IL-18 and plasma BNP values for predicting postdischarge RRT and/or 6-month mortality were determined, and receiver operating characteristic (ROC) curves were constructed by plotting sensitivity against (1-specificity). The area under the curves (AUCs) were calculated and analyzed by one-tailed test. Cutoff points were calculated by acquiring the best Youden index. All tests of P<0.05 was respected to be significant.
Results
Of 131 screened individuals, 11 died during hospitalization and 120 patients were followed up 6 months after discharge.
Baseline characteristics, values of renal and cardiac markers as well as outcomes of patients were presented in Table 1 . The average age of the patients included in this report was 69.3±11.8 years, and 65.6% of the patients were men. History of CKD was found in 35.9% of individuals, history of diabetes mellitus in 42.0% of patients, and hypertension in 68.7% of patients. The mean EF was 40.0±10.8 with systolic dysfunction (EF <50%) in 66.4%, and diastolic dysfunction (E/A <1) in 72.5% of patients. AKI was diagnosed in 46.8% of patients. The portion of patients who underwent RRT during hospitalization was 9.2% (12/131), and 5.8% (7/120) patients continued RRT after discharge. The in-hospital and 6-month mortality rate were 8.5% and 20%, respectively.
Concentrations of BUN (P < 0.001), serum creatinine (P < 0.001), as well as serum cystatin C (P < 0.001), serum IL-18 (P=0.001), urine IL-18 (P < 0.001), and plasma BNP (P < 0.001) were significantly higher in renal and/ or overall nonsurvivors when compared to renal and/ or overall survivors. APACHE II score (P < .001) and CCI score (P < 0.001) were significantly higher, while EF (P=0.032) was significantly lower in renal and/ or overall nonsurvivors in comparison to renal and/ or overall survivors. Furthermore, the incidences of CKD (P < 0.001), and diastolic dysfunction (abnormal relaxation) (P=0.002) were significantly higher in renal and/or overall non-survivors (Table 2) .
Univariate Cox analysis identified older age, higher concentration of BUN, serum creatinine, albuminuria, proteinuria, CRP, uric acid, serum cystatin C, serum and urine IL-18, plasma BNP, higher APACHE II and CCI score, severe systolic dysfunction, diastolic dysfunction (abnormal relaxation), previous history of CKD, new onset AKI, as well as lower values of mean arterial pressure, EF, eGFR, and lower urine output to be associated with postdischarge RRT and/or 6-month mortality ( Table 3 ). In multivariate Cox analysis urine IL-18, plasma BNP, APACHE II score and diastolic dysfunction (abnormal relaxation) were independent predictors for postdischarge RRT and/or 6-month mortality in patients with acute heart disorders ( Table 3) .
The ROC analysis confirmed that urine IL-18 and plasma BNP were the best predictors for postdischarge RRT and/or 6-month mortality in patients admitted for acute heart disorders. The ROC curve for urine IL-18 produced an AUC of 0.7 (P=0.003) with a sensitivity of 66.7% and specificity of 67.7% for the cutoff point of 29.1 pg/mL ( Figure 1 ). Figure 2 shows Kaplan-Meier curves displaying the association among concentrations of urine interleukin 18 and the composite outcome of postdischarge RRT and/or 6-month mortality in patients with acute heart disorders. Patients with the highest quartile of urine IL-18 (>139.92 pg/mL) experienced RRT and/or 6-month mortality 6.7 times more frequently in comparison to patients with second and third quartile of urine IL-18 (HR 6.7, 95% CI [2. [8] [9] [10] [11] [12] [13] [14] [15] [16] ; P < 0.0001). There was no statistically significant difference (P=0.38) between patients with second and third quartile of urine IL-18 (0.00-16.38 pg/mL and 16.39-139.91 pg/mL).
The ROC curve for plasma BNP produced an AUC of 0.76 (P < 0.001) with a sensitivity of 66.7% and specificity of 70.8% for the cutoff point of 881.6 pg/mL (Figure 1) . Figure 3 shows Kaplan-Meier curves displaying the relationship between concentrations of plasma BNP and the composite outcome of RRT and/or 6-month mortality in patients with acute heart disorders. Patients with baseline plasma concentrations of BNP >663.4 pg/mL reached the postdischarge RRT and/or 6-month mortality 3.01 times more frequently than patients with baseline plasma concentrations of BNP <663.4 pg/mL (HR 3.01, 95% CI [1.25-7.3]; P=0.014). BNP values were divided into two parts rather than quartiles because there was no significant difference between quartiles.
Discussion
In the present study, urine IL-18, plasma BNP, APACHE II score and left ventricular diastolic dysfunction predicted the risk of dialysis and/or 6-month mortality in patients hospitalized in ICUs for AHF and/or ACS. Patients with urine IL-18 concentrations >139.92 pg/mL and plasma BNP values >663.4 pg/mL were at significantly higher risk for postdischarge death and/or dialysis compared with patients with lower plasma BNP and urine IL-18 concentrations. Although of similar strength in univariate Cox analysis, the association of serum cystatin C and serum IL-18 with the postdischarged need for dialysis and/ or death was statistically insignificant after adjustment for clinical confounders in our multivariate Cox analysis.
IL-18 is a pro-inflammatory cytokine that is linked to accelerated atherosclerosis. Higher concentrations of serum IL-18 were detected in unstable atherosclerotic plaques in humans (19, 20) . In the patients diagnosed with ACS, the serum IL-18 levels showed prognostic value for predicting all-cause mortality and noncardiovascular mortality (21) . Although serum and urine IL-18 were both associated with adverse composite outcome of RRT and/or 6-month mortality in the present study, only urine IL-18 showed independent association in multivariate Cox analysis. Previous research confirmed that proximal tubule epithelial cells in the kidney express IL-18 only a few hours after renal injury. Therefore, increased levels of urine IL-18 are likely to be found in patients with acute tubular necrosis (22) . The utility of urine IL-18 as a marker of adverse renal outcome and mortality was already verified in the population of critically ill patients (7) . 
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Similarly to our results, this finding was mainly influenced by mortality, which was the predominant event in this composite outcome. In the patients admitted for acute hear failure, urine IL-18 was strongly associated with mortality, but it showed only modest ability to predict renal outcome (23) . However, our results confirmed the ability of urine IL-18 not only to predict 6-month mortality but also need for postdischarge dialysis. Kaplan-Meier curves displayed a strong relationship between the highest concentrations of urine IL-18 and the composite outcome of dialysis and/or mortality in patients with acute heart disorders.
Patients with the highest quartile of urine IL-18 (>139,92 pg/mL) were 6.7 times more likely to experience RRT and/or mortality in comparison with patients with second and third quartile of urine interleukin 18. Similarly to our results, heart surgery patients with the highest tertiles of peak urine IL-18 were linked to higher mortality risk compared with the patients with the lowest tertiles (24) . Association between elevated levels of urine IL-18 with dialysis and mortality can be explained by the ability of this renal biomarker to identify kidney injury, and possible further influence in damaging other vital organs in the body (25) . Severe AKI that require dialysis can be linked to long-term complications such as high mortality riks because of damaging distinct organs. The BNP is a hormone produced by cardiomyocytes as a response to ventricular dysfunction and increased myocardial stress. The previous investigation confirmed the diagnostic and prognostic importance of BNP in patients with HF (26) . However, a recent study showed the significant association of BNP with higher longterm mortality risk in patients diagnosed with ACS (27) . In ACS patients, levels of BNP are likely increasing due to stiffening of left ventricular as a result of myocardial ischemia. In the setting of HF, there is a well-described connection between ventricular dilatation, high central venous pressure (CVP) and renal dysfunction. As a result of increased CVP and renal congestion, glomerular filtration and sodium excretion are decreasing, therefore BNP has a physiologically important role in cardiorenal axis (28) . Nevertheless, the role of natriuretic peptides in predicting the maximum stage of AKI and the requirement of RRT was investigated only in critically ill patients admitted to intensive care unit for causes that excluded acute heart disorders (29) . To our best knowledge, the present study was the first to evaluate the role of BNP in predicting the composite outcome of dialysis and/or death after hospitalization for acute heart disorders. Kaplan-Meier curves displayed a strong relationship between concentrations of plasma BNP and the composite outcome of mortality and/or dialysis. AHF and/or ACS patients with baseline concentrations of plasma BNP >663.4 pg/ mL reached the endpoint (postdischarge mortality and/ or RRT) 3 times more frequently than patients with baseline plasma concentrations of BNP <663.4 pg/mL. Prognostic value of BNP in predicting dialysis was already investigated in patients with CKD stage 4 and 5. BNP concentration >140 ng/L predicted the requirement of dialysis in a 1-year and 5-year period, but there was no significant association between BNP and death in this patient population (30) . Different cutoff points of BNP in the present study and study of patients with CKD stages 4 and 5 can be explained with a rather high percentage of AHF (66.4%) as an underlying factor for the hospital admission in our study. Patients with acute heart disorders in the present study had a history of any stage of CKD in approximately one-third of patients (35.9%), but high prevalence of comorbidities such as LVH (77.1%), systolic dysfunction (66.4%) and diastolic dysfunction (72.5%). It is already established that plasma concentrations of BNP are increased as a combined consequence of impaired renal clearance, fluid overload, as well as systolic and diastolic heart dysfunction (31) . Diastolic dysfunction was also a predictor of RRT and/or death after hospitalization of patients with acute heart disorders in the present study. Previous studies confirmed the significance of diastolic dysfunction in predicting cardiovascular morbidity and mortality in the general population and population of patients treated with acute and chronic dialysis (32) (33) (34) . The present study confirmed that higher values of APACHE II score were independent predictors of RRT and/or 6-month mortality after hospital discharge of patients with acute heart disorders. The Acute Physiology and Chronic Health Evaluation is a prognosis scoring system that estimates the chance for mortality in ICUs. This scoring system is based on the evaluation of a large number of laboratory parameters, the clinical presentation of the patient as well as the presence of acute conditions and chronic comorbid diseases. Therefore, it was not surprising that we confirmed its prognostic value in the present study of individuals hospitalized in ICUs for AHF and/or ACS. Electrolyte, mineral and hemodynamic disturbances are common in individuals with acute heart disorders, and the APACHE II score reflects the extent of these disorders in severe patients. Previously, the APACHE II scoring system confirmed an independent association with mortality in coronary ICU patients and ICU patients diagnosed with AKI (10, 35) . However, in the present study, the APACHE II score predicted not only postdischarge mortality but also need for dialysis in patients with acute heart disorders. To the best of our knowledge, the ability of the APACHE II to predict RRT was evaluated only in the group of AKI patients so far. A recent study performed in China revealed that AKI patients with a high APACHE II score are more prone to receive dialysis (36) .
Conclusion
Urine IL-18, plasma BNP, APACHE II score and left ventricular diastolic dysfunction, at the time of hospital admission, provide valuable prognostic information for postdischarge dialysis risk and/or 6-month mortality in individuals with acute heart disorders.
Limitations of the study
The main restriction of the study was the fact that it was a single-center investigation that included relatively small number of patients. Furthermore, we analyzed selected, but not all potentially significant cardiorenal biomarkers. However, we monitored the prognostic value of biomarkers of renal injury and HF in the predicting postdischarge need for dialysis which has not been extensively studied in patients with acute heart disorders so far. Further studies on this subject are recommended.
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